57 citations
,
January 1986 in “The Prostate” This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.
9 citations
,
November 2021 in “Infectious Agents and Cancer” This study found that the active use of androgen deprivation therapy was not associated with a reduced risk of death in prostate cancer patients with COVID-19.
18 citations
,
July 2015 in “Drug Healthcare and Patient Safety” This review discusses the benefits and cardiovascular risks of androgen deprivation therapy for prostate cancer patients, noting that optimizing cardiovascular risk factors is important when using ADT.
4 citations
,
February 2024 in “The Journal of Urology” This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.
9 citations
,
September 2010 in “Dermatologic Therapy” This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.